STOCK TITAN

Nuvalent to Participate in the Cowen 42nd Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company specializing in targeted cancer therapies, will have CEO James Porter participate in the 'Lung Cancer Panel' at the Cowen 42nd Annual Healthcare Conference on March 9, 2022, at 9:10 a.m. ET. The event will be accessible via a live webcast on the company's investor website, which will be archived for 30 days. Nuvalent is advancing treatments for ROS1-positive and ALK-positive non-small cell lung cancer, focusing on overcoming existing therapy limitations.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., March 2, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will participate in a virtual panel titled, "Lung Cancer Panel," during the Cowen 42nd Annual Healthcare Conference on Wednesday, March 9, 2022, at 9:10 a.m. ET.

A live webcast will be available in the investor section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), along with multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at www.nuvalent.com. Follow us on Twitter (@nuvalent) and LinkedIn.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-cowen-42nd-annual-healthcare-conference-301493403.html

SOURCE Nuvalent, Inc.

FAQ

When will Nuvalent participate in the Cowen 42nd Annual Healthcare Conference?

Nuvalent will participate in the Cowen 42nd Annual Healthcare Conference on March 9, 2022, at 9:10 a.m. ET.

Who is representing Nuvalent at the healthcare conference?

James Porter, Ph.D., the CEO of Nuvalent, will represent the company at the conference.

Where can I watch the Nuvalent healthcare conference presentation?

The presentation will be available via a live webcast on Nuvalent's investor website, with an archive accessible for 30 days.

What is the focus of Nuvalent's research?

Nuvalent focuses on developing targeted therapies for ROS1-positive and ALK-positive non-small cell lung cancer.

What is Nuvalent's stock symbol?

Nuvalent's stock symbol is NUVL.

Nuvalent, Inc.

NASDAQ:NUVL

NUVL Rankings

NUVL Latest News

NUVL Stock Data

6.27B
64.36M
2.89%
103.24%
7.37%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE